Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
| Revenue (TTM) | $79.67B |
| Gross Profit (TTM) | $66.44B |
| EBITDA | $41.71B |
| Operating Margin | 54.20% |
| Return on Equity | 102.30% |
| Return on Assets | 20.40% |
| Revenue/Share (TTM) | $89.02 |
| Book Value | $38.00 |
| Price-to-Book | 30.28 |
| Price-to-Sales (TTM) | 14.07 |
| EV/Revenue | 13.45 |
| EV/EBITDA | 25.70 |
| Quarterly Earnings Growth (YoY) | 26.20% |
| Quarterly Revenue Growth (YoY) | 47.70% |
| Shares Outstanding | $891.74M |
| Float | $888.94M |
| % Insiders | 0.16% |
| % Institutions | 85.35% |
Volatility is currently expanding
Eli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide. The company's latest approval strengthens its diabetes portfolio.
Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the dust.
The study used Novo Nordisk's semaglutide to arrive at its results. The news should only cause the market for GLP-1 drugs to grow faster.
The sale has nothing to do with the stock's potential, however. And Lilly remains well positioned to continue winning the GLP-1 race.
Eli Lilly stock today trades above $1,160 and has reached record highs this year. The pharma giant is benefiting from the GLP-1 drug boom.
INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use Across both types of inflammatory bowel disease, including patients with prior biologic failure, achieving comprehensive disease control or corticosteroid-free deep remission was associated with improved patient-reported outcomes INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- New data analyses from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at one year, as measured by comprehensive disease control in UC and corticosteroid-free deep remission in Crohn's disease. These multidimensional outcomes were observed even in patients with prior biologic failure, a population often facing greater treatment challenges.
In Q3 2026, the Portfolio returned 4.46% (net of fees) compared to 0.92% for the Index. Top relative contributors to the Portfolio's performance included ServiceNow, Shopify and Microsoft. By contrast, the largest relative detractors in the quarter were Nvidia, Apple (not owned) and Lam Research.
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LLY and any ticker you trade — then tracks every position and per-strategy win rate.
